Geneart | GenomeWeb


In Brief This Week is a column containing news items that our readers may have missed during the week.

The firm, which now majority-owned by Life Technologies, also posted a sharp gain in its earnings before interest and taxes.

Life Tech now owns 74 percent of the synthetic gene company.

Life Technologies has made a tender offer to acquire the remaining shares of Geneart that it does not already own for around €25.5 million. The total purchase price was approximately €56 million.

The agreement gives Applied Biosystems Deutschland approximately 58 percent of GeneArt's shares.

A proposed HHS guidance for synthetic biology roughly fits a harmonization effort started by the International Gene Synthesis Consortium.

Five firms have formed the International Gene Synthesis Consortium to set gene and customer screening protocols that address security concerns.

The firm's sales increased despite the expiration of an NIH contract.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.